Peptide Research Hub
Educational reference
Educational reference only. Nothing on this site is medical advice. Many compounds described here are not FDA-approved, lack adequate human evidence, and may be illegal in your jurisdiction. Always consult a licensed clinician.

Metabolic & GLP-1/GIP Agonists

Retatrutide

Also known as: LY3437943

Evidence: Moderate clinical Disclaimer: Critical Investigational

Mechanism & research context

Investigational triple agonist (GLP-1 / GIP / glucagon receptors) currently in Phase 3 development.

Safety flags

1 flag
  • High severity regulatory_action

    Not FDA-approved. FDA has issued repeated warnings against unapproved GLP-1-class compounds compounded or sold for weight loss.

    Source ↗

Research papers

16 records

Citation links route to PubMed, Europe PMC, and PMC. Presence of a study is not endorsement. Records are refreshed from PubMed on a regular cadence; rows marked “Live search link” will resolve to a current PubMed search until a full citation has been ingested.

Clinical trials

21 records
  • Live search Live search

    Live ClinicalTrials.gov search: Retatrutide

    Condition: See live results

    Open on ClinicalTrials.gov ↗
  • NCT03841630 PHASE1 COMPLETED

    A Single-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3437943 in Healthy Subjects

    Condition: Healthy

    Sponsor: Eli Lilly and Company

    Open on ClinicalTrials.gov ↗
  • NCT04143802 PHASE1 COMPLETED

    A Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3437943 in Patients With Type 2 Diabetes Mellitus

    Condition: Diabetes Mellitus, Type 2

    Sponsor: Eli Lilly and Company

    Open on ClinicalTrials.gov ↗
  • NCT04823208 PHASE1 COMPLETED

    A Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus

    Condition: Diabetes Mellitus, Type 2

    Sponsor: Eli Lilly and Company

    Open on ClinicalTrials.gov ↗
  • NCT04867785 PHASE2 COMPLETED

    A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo and Dulaglutide in Participants With Type 2 Diabetes

    Condition: Type 2 Diabetes

    Sponsor: Eli Lilly and Company

    Open on ClinicalTrials.gov ↗
  • NCT04881760 PHASE2 COMPLETED

    A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities

    Condition: Obesity; Overweight

    Sponsor: Eli Lilly and Company

    Open on ClinicalTrials.gov ↗
  • NCT05445232 PHASE1 COMPLETED

    A Multiple-Dose Drug-Drug Interaction Study to Determine the Effect of LY3437943 on Drug Metabolizing Enzymes

    Condition: Obesity

    Sponsor: Eli Lilly and Company

    Open on ClinicalTrials.gov ↗
  • NCT05548231 PHASE1 COMPLETED

    A Multiple Dose Escalation Study in Chinese Participants With Overweight BMI or Obesity to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3437943

    Condition: Overweight; Obesity

    Sponsor: Eli Lilly and Company

    Open on ClinicalTrials.gov ↗
  • NCT05916560 PHASE1 COMPLETED

    A Parallel-Group, Single-Dose, Phase 1, Open-Label Study to Investigate the Pharmacokinetics of LY3437943 in Participants With Hepatic Impairment Compared With Healthy Participants

    Condition: Healthy; Hepatic Insufficiency

    Sponsor: Eli Lilly and Company

    Open on ClinicalTrials.gov ↗
  • NCT05929079 PHASE3 ACTIVE_NOT_RECRUITING

    A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight: A Randomized Double-Blind, Placebo-Controlled Trial

    Condition: Type 2 Diabetes; Obesity; Overweight; Obstructive Sleep Apnea

    Sponsor: Eli Lilly and Company

    Open on ClinicalTrials.gov ↗
  • NCT05931367 PHASE3 COMPLETED

    A Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee: A Randomized, Double-Blind, Placebo-Controlled Trial

    Condition: Obesity; Overweight; Osteo Arthritis Knee

    Sponsor: Eli Lilly and Company

    Open on ClinicalTrials.gov ↗
  • NCT05936151 PHASE2 COMPLETED

    A Phase 2b, Double-Blind Study to Investigate the Effect of Retatrutide on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

    Condition: Overweight or Obesity; CKD; Type 2 Diabetes

    Sponsor: Eli Lilly and Company

    Open on ClinicalTrials.gov ↗
  • NCT06003465 PHASE1 COMPLETED

    A Relative Bioavailability Study to Compare the Pharmacokinetics of LY3437943 Administered Subcutaneously by a Test Device (Test Formulation) Versus Reference Device (Reference Formulation) in Healthy Participants

    Condition: Healthy

    Sponsor: Eli Lilly and Company

    Open on ClinicalTrials.gov ↗
  • NCT06260722 PHASE3 ACTIVE_NOT_RECRUITING

    A Phase 3, Randomized, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Semaglutide Once Weekly in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)

    Condition: Diabetes Mellitus, Type 2

    Sponsor: Eli Lilly and Company

    Open on ClinicalTrials.gov ↗
  • NCT06313528 PHASE1 COMPLETED

    A Randomized, Double-Blind, Phase 1 Study to Investigate the Effect of LY3437943 Versus Placebo on Calorie Intake and Energy Expenditure in Participants With Obesity Under Calorie Restriction

    Condition: Obesity

    Sponsor: Eli Lilly and Company

    Open on ClinicalTrials.gov ↗
  • NCT06354660 PHASE3 COMPLETED

    A Phase 3, Randomized, Multicenter, Double-Blind Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)

    Condition: Diabetes Type 2

    Sponsor: Eli Lilly and Company

    Open on ClinicalTrials.gov ↗
  • NCT06383390 PHASE3 ACTIVE_NOT_RECRUITING

    A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and Major Adverse Kidney Events in Participants With Body Mass Index ≥27 kg/m2 and Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease

    Condition: Atherosclerotic Cardiovascular Disease (ASCVD); Chronic Kidney Disease (CKD)

    Sponsor: Eli Lilly and Company

    Open on ClinicalTrials.gov ↗
  • NCT06662383 PHASE3 ACTIVE_NOT_RECRUITING

    A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Retatrutide Compared to Tirzepatide in Adults Who Have Obesity

    Condition: Obesity

    Sponsor: Eli Lilly and Company

    Open on ClinicalTrials.gov ↗
  • NCT06808802 PHASE1 COMPLETED

    A Phase 1, Open-label, Single-arm Study to Investigate the Effect of Retatrutide on Metoprolol Pharmacokinetics in Healthy Participants

    Condition: Healthy

    Sponsor: Eli Lilly and Company

    Open on ClinicalTrials.gov ↗
  • NCT06982846 PHASE1 ACTIVE_NOT_RECRUITING

    A Randomized, Placebo-Controlled, Parallel Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia

    Condition: Type 2 Diabetes Mellitus

    Sponsor: Eli Lilly and Company

    Open on ClinicalTrials.gov ↗
  • NCT07226947 NA RECRUITING

    BIA Monitoring and Exercise for the Prevention of Muscle Loss With Incretin Therapy (BICEP Study)

    Condition: Obesity; Body Composition

    Sponsor: Massachusetts General Hospital

    Open on ClinicalTrials.gov ↗

Doses reported in studies

0 records
This is not a dosing guide. Entries below are historical metadata transcribed verbatim from a cited clinical-trial protocol, published study, or FDA-approved label. They describe what was administered in a specific study population under medical supervision — they are not recommendations, not common-use guidance, and may not be safe or appropriate outside the cited context. Doses widely discussed in community/anecdotal sources are not shown here; see the safety policy for why.

No study-protocol dose records have been curated for Retatrutide yet. Absence of records is not evidence of safety — many peptides lack adequate human-trial data in the first place.

Records here are populated from public sources only (ClinicalTrials.gov protocol summaries and FDA-approved labels) and must cite a verifiable source URL. They are not added from forum posts, vendor pages, anecdotal write-ups, or social media.

These entries describe what was studied. They do not tell you what to take, how to reconstitute anything, how to fill a capsule, how often to administer, or where to obtain a compound. If you are considering use of Retatrutide, those decisions belong with a licensed clinician working from the full label or trial record — not from this summary.

Why this page does not list a dose for self-use

The "Doses reported in studies" section above (when populated) describes what was administered in a cited study or label, under medical supervision, in a specific population. It is not a dosing guide for self-use. Separately, we do not publish anecdotal or community-reported dose ranges, administration methods, vial concentrations, or capsule masses for Retatrutide. Anecdotal figures for unapproved compounds are not harm-reduction data: they lack denominators for adverse events, cannot account for individual physiology or compound purity, and normalise unsupervised use. See the safety policy for the full reasoning.

If this compound has an FDA-approved label

If a label exists, the regulator-reviewed dosing and administration information is there — read it in the context of a prescriber's evaluation.

Questions worth bringing to a clinician

  • What is the evidence for this compound in someone with my history?
  • What are the realistic, regulator-reviewed alternatives?
  • What would you monitor, and what would make you stop?

If you have already taken a peptide and feel unwell: contact emergency services. In the United States, Poison Control is reachable 24/7 at 1-800-222-1222. Do not wait for a community thread.

Research peptides are not substitutes for medical care. If you are considering any peptide for health purposes, speak with a board-certified physician or endocrinologist first.